MIT spinout from Sangeeta Bhatia’s lab gets a $22M round to develop new disease and drug sensors
Bioengineering wiz Sangeeta Bhatia has helped spin out a new biotech company from her MIT lab that will now look to test and eventually commercialize new “activity sensors” that can both flag diseases as well as monitor a patient’s response to a drug.
The company is Glympse, which has surfaced occasionally in semi-stealth mode after India’s Kiran Mazumdar-Shaw and Theresia Gouw at Aspect Ventures seeded the effort with $6.6 million in 2015. Now a much bigger syndicate has come along to inject a $22 million launch round into the venture.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
